Tomoya Shimokata

Nagoya, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated With Trastuzumab and Pertuzumab.

Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated With Trastuzumab and Pertuzumab.

Journal: Circulation reports

Published: February 21, 2025

Influence of renal function on the clinical efficacy of carboplatin plus pemetrexed in patients with non-small cell lung cancer.

Influence of renal function on the clinical efficacy of carboplatin plus pemetrexed in patients with non-small cell lung cancer.

Journal: Nagoya journal of medical science

Published: November 16, 2024

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study.

Journal: Cancer immunology, immunotherapy : CII

Published: March 28, 2024

Long-term response to MEK inhibitor monotherapy in a patient with papillary thyroid carcinoma harboring BRAF V600E mutation.

Long-term response to MEK inhibitor monotherapy in a patient with papillary thyroid carcinoma harboring BRAF V600E mutation.

Journal: International cancer conference journal

Published: January 21, 2024

Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team.

Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 16, 2024

Potential drug interactions between pazopanib and proton pump inhibitors/potassium-competitive acid blockers in patients with soft tissue sarcoma.

Potential drug interactions between pazopanib and proton pump inhibitors/potassium-competitive acid blockers in patients with soft tissue sarcoma.

Journal: International cancer conference journal

Published: August 28, 2023

Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review.

Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review.

Journal: International cancer conference journal

Published: July 08, 2023

Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer.

Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer.

Journal: Cancer medicine

Published: November 28, 2022

A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal.

A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal.

Journal: International cancer conference journal

Published: March 22, 2022

Correction to: Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment.

Correction to: Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment.

Journal: International cancer conference journal

Published: February 07, 2022

Direct Observation of Retinal Microvessels in Cancer Patients After Systemic Administration of Bevacizumab and Oxaliplatin.

Direct Observation of Retinal Microvessels in Cancer Patients After Systemic Administration of Bevacizumab and Oxaliplatin.

Journal: Cancer diagnosis & prognosis

Published: January 31, 2022

Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline.

Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline.

Journal: The Journal of clinical endocrinology and metabolism

Published: September 22, 2021

Showing 1-12 of 52

Last Updated: 09/26/2026